MP0112 (0.4 mg) [clinicaltrials_resource:NCT01086761/group/B3]
Single 0.4 mg intravitreal injection of MP0112 in the study eye.
group [clinicaltrials_vocabulary:group]
NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/03ee3a5ccea4aa28183d3cff783eb594]NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/499d79470f0dd96e7162ad5f24ad4955]NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/9e08bb5c8503d381503888b6e00a2f01]
group id [clinicaltrials_vocabulary:group-id]
MP0112 (0.4 mg) [clinicaltrials_resource:NCT01086761/group/B3]
Single 0.4 mg intravitreal injection of MP0112 in the study eye.
Bio2RDF identifier
NCT01086761/group/B3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT01086761/group/B3
group id [clinicaltrials_vocabulary:group-id]
description
Single 0.4 mg intravitreal injection of MP0112 in the study eye.
@en
identifier
clinicaltrials_resource:NCT01086761/group/B3
title
MP0112 (0.4 mg)
@en
type
label
MP0112 (0.4 mg) [clinicaltrials_resource:NCT01086761/group/B3]
@en